Biotech News
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
investors.maxcyte.com2026-05-06 14:58 EST
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a